- Conditions
- Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
- Interventions
- BOLD-100 +/- FOLFOX Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
- Drug
- Lead sponsor
- Bold Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Santa Monica, California • Tampa, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 1,004
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Locally Advanced Esophageal or GE Junction Cancer
- Interventions
- AT-101
- Drug
- Lead sponsor
- Ascenta Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Unresectable Metastatic Colorectal Cancer
- Interventions
- CYAD-101, FOLFOX, Pembrolizumab
- Drug
- Lead sponsor
- Celyad Oncology SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2038
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Tampa, Florida
- Conditions
- Anal Cancer
- Interventions
- cetuximab, cisplatin, fluorouracil, radiotherapy
- Biological · Drug · Radiation
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2021
- U.S. locations
- 125
- States / cities
- Stanford, California • Fort Collins, Colorado • Chicago, Illinois + 88 more
- Conditions
- Adenocarcinoma of the Colon, Stage III Colon Cancer
- Interventions
- leucovorin calcium, fluorouracil, irinotecan hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7
- Interventions
- Bevacizumab, Capecitabine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, Radiation Therapy, Therapeutic Conventional Surgery
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • New Britain, Connecticut • Atlanta, Georgia + 66 more
- Conditions
- Solid Tumor
- Interventions
- Cetuximab, Cisplatin, 5 - Fluorouracil
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 5
- States / cities
- Fayetteville, Arkansas • Fairway, Kansas • Reno, Nevada + 2 more
- Conditions
- Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus, Unresectable Adenocarcinoma of Gastric Cardia, Metastatic Adenocarcinoma of Gastric Cardia
- Interventions
- FOLFOX, 5-FU, Erlotinib
- Drug
- Lead sponsor
- Translational Oncology Research International
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Squamous Cell Carcinoma of the Anus
- Interventions
- Cisplatin, 5-Fluorouracil (5-FU), Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- Royal Marsden NHS Foundation Trust
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Colorectal Neoplasms, Neoplasms
- Interventions
- sunitinib + FOLFOX
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Nashville, Tennessee • Dallas, Texas
- Conditions
- Pancreatic Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma
- Interventions
- Oxaliplatin, Docetaxel, Leucovorin, Irinotecan, 5-Fluorouracil
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Actinic Keratoses
- Interventions
- 5% 5-fluorouracil (5-FU) powder, 5% 5-fluorouracil (5-FU) powder PLUS 15% Aluminum Chloride Hexahydrate (ACH)
- Drug
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Pancreatic Cancer
- Interventions
- panitumumab, capecitabine, fluorouracil, gemcitabine hydrochloride, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 281
- States / cities
- Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 173 more
- Conditions
- Gastrointestinal Cancer, Head and Neck Cancer, Breast Cancer, Chemotherapy Effect, 5-Fluorouracil Toxicity
- Interventions
- Arterial blood pressure, Skin microcirculatory blood flow, Brachial artery blood flow, Venous blood draw
- Other
- Lead sponsor
- Kansas State University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Manhattan, Kansas
- Conditions
- Stage IB Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIC Esophageal Adenocarcinoma
- Interventions
- Paclitaxel, Carboplatin, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Radiation Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Abraxane, Cetuximab, Cisplatin, 5-FU, Radiation (Post induction)
- Drug · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Amivantamab, Pembrolizumab, Carboplatin, 5-Flurouracil, Cisplatin
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 49
- States / cities
- Chandler, Arizona • Tucson, Arizona • Fullerton, California + 43 more
- Conditions
- Pancreatic Cancer
- Interventions
- Phase I: XB2001 250 mg, Phase I: XB2001 500 mg, Phase I: XB2001 1000 mg, Phase II: XB2001 1000 mg, Phase II: Placebo
- Biological
- Lead sponsor
- XBiotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 30
- States / cities
- Tucson, Arizona • Burbank, California • Cerritos, California + 26 more
- Conditions
- Breast Cancer
- Interventions
- Paclitaxel, Eribulin, 5-Fluorouracil, Epirubicin, Cyclophosphamide, Doxorubicin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Anal Cancer
- Interventions
- Treatment, 5FU, Mitomycin, IMRT
- Biological · Drug · Radiation
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 3
- States / cities
- New York, New York • Providence, Rhode Island
- Conditions
- Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Interventions
- FOLFIRINOX, Oxaliplatin, Leucovorin, Irinotecan, 5-Fluorouracil (5-FU), NIS793, Chemoradiation, Capecitabine, Radiation Therapy, Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- Colin D. Weekes, M.D., PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent), 5-fluorouracil (5-FU), Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Bakersfield, California • Cerritos, California + 32 more
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Drug
- Lead sponsor
- Robert H. Lurie Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more
- Conditions
- Esophageal Cancer
- Interventions
- filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 97
- States / cities
- Burbank, California • Hayward, California • Mission Hills, California + 72 more